Man Group’s Zevra Therapeutics ZVRA Stock Holding History

Man Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-92,347	Closed	-$827K	–	2614
2025 Q4	$827K	Buy	92,347 +58,695	+174%	+$555K	﹤0.01%	1730
2025 Q3	$320K	Buy	+33,652	New	+$337K	﹤0.01%	1981
2025 Q2	–	Sell	-22,448	Closed	-$168K	–	2446
2025 Q1	$168K	Buy	+22,448	New	+$178K	﹤0.01%	2058
2023 Q1	–	Sell	-33,046	Closed	-$175K	–	1929
2022 Q4	$152K	Buy	33,046 +3,768	+13%	+$19.1K	﹤0.01%	1825
2022 Q3	$183K	Buy	+29,278	New	+$166K	﹤0.01%	1786
2022 Q2	–	Hold	0	–	–	–	1725

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Man Group's ZVRA Position: Q1 2026 in Review

Man Group sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 92,347 shares — an estimated $827K sold.

Man Group first reported a position in ZVRA in Q3 2022 and held it in 5 quarters. The position peaked at $827K in Q4 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

Man Group reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
Man Group sold 92,347 Zevra Therapeutics shares in Q1 2026, an estimated $827K.
Man Group first reported a position in Zevra Therapeutics in Q3 2022 and held it in 5 quarters.
Man Group's Zevra Therapeutics position peaked at $827K in Q4 2025.
148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.